Ogawa M, Yamashita S, Sakamoto K, Ikei S
Department of Surgery II, Kumamoto University Medical School, Japan.
Res Commun Chem Pathol Pharmacol. 1991 Nov;74(2):241-4.
We demonstrated the elevation of serum Group II phospholipase A2 (PLA2) in 56.5% of patients with cancers of digestive organs. The elevation of serum Group II PLA2 was more frequently seen in patients with advanced or metastasized cancer than in those with early cancer (66.7 vs. 35.0%). There was no correlation between serum Group II PLA2 and carcinoembryonic antigen (CEA) in these patients. A combined assay of Group II PLA2 and CEA increased the sensitivity of detection of all, early and advanced cancers from 37.1, 15.0 and 47.6% with CEA alone to 71.0, 45.0 and 83.3%, respectively.
我们证实，56.5%的消化器官癌症患者血清II组磷脂酶A2（PLA2）升高。血清II组PLA2升高在晚期或转移性癌症患者中比早期癌症患者更常见（66.7%对35.0%）。在这些患者中，血清II组PLA2与癌胚抗原（CEA）之间无相关性。II组PLA2和CEA联合检测使所有癌症、早期癌症和晚期癌症的检测敏感性分别从单独检测CEA时的37.1%、15.0%和47.6%提高到71.0%、45.0%和83.3%。
